FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 359:1309-1312 September 25, 2008 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In July of this year, the American Academy of Pediatrics (AAP) released revised recommendations for the management of hypercholesterolemia in children (see table).¹ Within days after publication, the new policy statement had elicited a firestorm of controversy — including hundreds of print and broadcast news stories, editorials in the New York Times and the Boston Globe, and thousands of Internet postings — that took many members of the pediatrics community by surprise. The AAP and the National Cholesterol Education Program have advocated targeted screening and pharmacologic treatment for nearly two decades. What sparked this sudden flurry of media attention?

View this table:   . . . [Full Text of this Article]

 

Source Information

Dr. de Ferranti is director of the Preventive Cardiology Clinic at Children's Hospital Boston and an assistant professor of pediatrics at Harvard Medical School, in Boston. Dr. Ludwig is director of the Optimal Weight for Life Program at Children's Hospital Boston and an associate professor of pediatrics at Harvard Medical School.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.